A dual-response drug-releasing mofs@ibu nanofiber transdermal sustained-release material and its preparation method and application

A nanofiber and sustained-release material technology, applied in the field of biomedical materials, can solve problems such as severe gastrointestinal and side effects, and achieve the effects of single product, less side reactions, and mild preparation conditions

Active Publication Date: 2022-08-02
SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, traditional ibuprofen oral preparations (such as tablets) will show more serious gastrointestinal side effects, and patients may also have adverse reactions such as palpitations, nausea, and dizziness.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A dual-response drug-releasing mofs@ibu nanofiber transdermal sustained-release material and its preparation method and application
  • A dual-response drug-releasing mofs@ibu nanofiber transdermal sustained-release material and its preparation method and application
  • A dual-response drug-releasing mofs@ibu nanofiber transdermal sustained-release material and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] A preparation method of MOFs@IBU nanofiber transdermal sustained-release material with dual-response drug release, comprising the steps of:

[0042] (1) Weigh 0.0505g of ligand 4,4'-((4-(4H-1,2,4-triazol-4-yl)benzene)azodioyl)dibenzoic acid, 0.074g of hexahydrate Zinc nitrate and 0.0505g of ibuprofen API were dissolved in 30ml of mixed solvent of pure water and N,N-dimethylformamide (DMF) (pure water: N,N-dimethylformamide (DMF) = 1:1 (v / v)), add 150uL of diethanolamine (DEA), and mix well. After standing at room temperature for 24 h, centrifugal filtration, washing with DMF three times, and vacuum drying at 63 °C to obtain a brown powder solid, namely MOFs@IBU solid. The microscopic morphology of the obtained MOFs@IBU is a flower-shaped structure with a particle size of 90-400 nm.

[0043] (2) 0.7 g of polyacrylonitrile (PAN, weight average molecular weight Mw=8 5000) was weighed and dissolved in 10 ml of N,N-dimethylformamide (DMF) to prepare a solution. 0.028 g of...

Embodiment 2

[0046] A preparation method of MOFs@IBU nanofiber transdermal sustained-release material with dual-response drug release, comprising the steps of:

[0047] (1) Weigh out 0.0505g ligand 4,4'-((4-(4H-1,2,4-triazol-4-yl)benzene)azodioyl)dibenzoic acid and 0.0555g hexahydrate Zinc nitrate and 0.0505g of ibuprofen API were dissolved in 30ml of mixed solvent of pure water and N,N-dimethylformamide (DMF) (pure water: N,N-dimethylformamide (DMF) = 1:1 (v / v)), and add diethanolamine (DEA) 140uL, mix well. After standing at room temperature for 24 h, centrifugal filtration, washing with DMF three times, and vacuum drying at 68 °C to obtain a brown powder solid, namely MOFs@IBU solid. figure 1 For the SEM images of the resulting MOFs@IBU, from figure 1 It can be seen that the as-prepared MOFs@IBU have a flower-shaped structure with a size of about 90–300 nm.

[0048] (2) 0.7 g of polyacrylonitrile (PAN, weight-average molecular weight Mw=150000) was weighed and dissolved in 10 ml of N...

Embodiment 3

[0051] A preparation method of MOFs@IBU nanofiber transdermal sustained-release material with dual-response drug release, comprising the steps of:

[0052] (1) Weigh out 0.0505g ligand 4,4'-((4-(4H-1,2,4-triazol-4-yl)benzene)azodioyl)dibenzoic acid and 0.074g hexahydrate Zinc nitrate and 0.101g of ibuprofen API were dissolved in 30ml of mixed solvent of pure water and N,N-dimethylformamide (DMF) (pure water: N,N-dimethylformamide (DMF) = 1:1 (v / v)), add 150uL of diethanolamine (DEA), and mix well. After standing at room temperature for 24 h, centrifugal filtration, washing with DMF three times, and vacuum drying at 70 °C to obtain a brown powder solid, namely MOFs@IBU solid. figure 2 For the SEM images of the resulting MOFs@IBU, from figure 2 It can be seen that the as-prepared MOFs@IBU have a flower-shaped structure with a size of about 90–300 nm.

[0053] (2) 0.7 g of polyacrylonitrile (PAN, weight-average molecular weight Mw=150000) was weighed and dissolved in 10 ml o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention provides a MOFs@IBU nanofiber transdermal sustained-release material with dual-response drug release and a preparation method and application thereof. The preparation method of the sustained-release material comprises the steps of: mixing ligand 4, 4'-((4-(4H-1,2,4-triazol-4-yl)benzene)azodioyl)dibenzoic acid, Zinc nitrate and ibuprofen were dissolved in a mixed solvent of water and N,N-dimethylformamide, and diethanolamine (DEA) was added to mix them evenly. The reaction was allowed to stand at room temperature for 20-30h, and the MOFs were obtained by centrifugation, washing and drying. @IBU; Dissolve polyacrylonitrile in N,N-dimethylformamide (DMF), add MOFs@IBU, mix and disperse uniformly to obtain spinning solution; then electrospin and dry to obtain. The nanofiber membrane obtained by the invention has the drug release capability of dual response of pH and temperature; the preparation process is simple, the energy consumption is low, the structure of the drug-carrying system is easy to control, and the cost is low.

Description

technical field [0001] The invention relates to a MOFs@IBU nanofiber transdermal sustained-release material with dual-response drug release, a preparation method and application thereof, and belongs to the field of biomedical materials. Background technique [0002] MOFs (Metal-Organic Frameworks) are metal-organic framework compounds, which are composed of inorganic metal centers (metal ions or metal clusters) and bridged organic ligands connected to each other through self-assembly, forming a class of periodic network structures. Porous material. It is different from both inorganic porous materials and general organic complexes. It combines the rigidity of inorganic materials and the flexibility of organic materials, and has a wide range of applications in the fields of gas separation, catalysis, sensing and drug loading. In the field of pharmacy, MOFs materials loaded with drugs have attracted much attention. MOFs materials loaded with drugs have the following advantages...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/70A61K31/192A61K47/32A61K47/69A61P29/00D04H1/43D04H1/728D04H3/007D04H3/02
Inventor 张平平程诗鸿王秋香张艳艳晁姝姝高照菊
Owner SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap